Annals of Internal MedicineStockholm3–Magnetic Resonance Imaging Population-Based Prostate Cancer Screening Study: Two-Year Follow-up

✅ Clinical Decision Support / Validated Tool

PSA-based prostate cancer screening remains controversial because of concerns regarding overdiagnosis and missed clinically significant disease. In a population-based Swedish screening cohort, investigators compared PSA with the Stockholm3 risk model, which incorporates biomarkers, genetics, and clinical variables.

Clinical Considerations

• Stockholm3 achieved 90% sensitivity for clinically significant prostate cancer versus 74% for PSA.
• False-negative rates were 10% with Stockholm3 compared with 26% using PSA screening.
• Specificity remained similar between strategies, at 89% for Stockholm3 and 90% for PSA.
• Decision-curve analysis indicated greater net clinical benefit through fewer unnecessary biopsies and fewer missed significant cancers.

Practice Applications

• Consider risk-stratified screening approaches beyond PSA alone.
• Interpret improved sensitivity alongside similar specificity when evaluating screening strategies.
• Recognize MRI-integrated pathways as an important component of contemporary prostate screening.
• Monitor longer-term follow-up before drawing conclusions regarding mortality benefit.